Phase II Study of IMC-A12 in Metastatic Uveal Melanoma.

Trial Profile

Phase II Study of IMC-A12 in Metastatic Uveal Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Cixutumumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Dec 2012 Planned end date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 26 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Sep 2012 Planned end date changed from 1 Aug 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top